================================================================================
                    SITE MASTER FILE
                    BIOPHARMA INDUSTRIES LIMITED
                    THANE MANUFACTURING FACILITY
================================================================================

                    Prepared in accordance with:
                    - WHO Technical Report Series No. 961, 2011, Annex 6
                    - PIC/S Guidance PE 008-4
                    - EU GMP Annex 2.5

================================================================================

Document Number:      SMF/THA/001
Version:              5.0
Effective Date:       January 1, 2025
Review Date:          December 31, 2025
Prepared By:          Mrs. Deepika Jain, Head of Quality Assurance
Approved By:          Dr. Ramesh Kulkarni, Managing Director

================================================================================

TABLE OF CONTENTS

1. General Information
2. Quality Management System
3. Personnel
4. Premises and Equipment
5. Documentation
6. Production
7. Quality Control
8. Distribution, Complaints, Product Defects and Recalls
9. Self-Inspection
10. Appendices

================================================================================

1. GENERAL INFORMATION
=====================

1.1 CONTACT INFORMATION

Company Name:           BioPharma Industries Limited
Site Address:           Plot No. 234-235, MIDC Industrial Area
                        Thane-Belapur Road, Rabale
                        Thane - 400701, Maharashtra, India

Telephone:              +91-22-2568-XXXX
Fax:                    +91-22-2568-XXXX
Email:                  regulatory@biopharma.com
Website:                www.biopharma.com

Corporate Identification Number (CIN): U24230MH2012PLC234567
GPS Coordinates:        19.1234° N, 73.0234° E

24-Hour Emergency Contact:
Name:                   Dr. Rajendra Patil (Technical Director)
Phone:                  +91-98XXX-XXXXX

1.2 AUTHORIZED MANUFACTURING ACTIVITIES

Drug Manufacturing License: MH/25D/2013/1234
Issued By:              Food and Drug Administration, Maharashtra
Valid Until:            March 14, 2028

The site is authorized to manufacture:
- Tablets (film-coated, uncoated, enteric-coated)
- Hard gelatin capsules
- Beta-lactam products in dedicated facilities

1.3 OTHER MANUFACTURING ACTIVITIES ON SITE

No other manufacturing activities are carried out at this site.
The site is dedicated exclusively to pharmaceutical manufacturing.

1.4 REGULATORY INSPECTIONS (LAST 5 YEARS)

Date            Authority                 Type              Outcome
--------------------------------------------------------------------------------
Apr 2021        FDA Maharashtra           Routine           3 minor observations
Sep 2022        FDA Maharashtra           Complaint         No adverse findings
Jan 2024        WHO Prequalification      GMP Certification Zero critical, 3 minor
Aug 2024        FDA Maharashtra           Annual            Clean inspection

No warning letters, import alerts, or regulatory actions in site history.

================================================================================

2. QUALITY MANAGEMENT SYSTEM
===========================

2.1 QMS OVERVIEW

The site operates a comprehensive Quality Management System based on:
- ICH Q10 Pharmaceutical Quality System
- WHO GMP guidelines
- Schedule M of Drugs and Cosmetics Rules, India

2.2 QUALITY POLICY

BioPharma Industries is committed to manufacturing pharmaceutical products
that consistently meet quality specifications, regulatory requirements, and
customer expectations. We achieve this through:
- Compliance with GMP and applicable regulations
- Continuous improvement of processes and systems
- Training and empowering our personnel
- Prevention of contamination and errors

2.3 QUALITY MANUAL

A Quality Manual (Document No. QM/001) describes the QMS structure including:
- Quality policy and objectives
- Organizational structure
- Key processes and their interactions
- Roles and responsibilities

2.4 PRODUCT QUALITY REVIEW (PQR)

Annual Product Quality Reviews are conducted for all products covering:
- Batch analysis trends
- Deviation and CAPA analysis
- Change control review
- Stability data trends
- Complaint analysis
- Supplier performance
- Process capability

2.5 CHANGE CONTROL

All changes are managed through a formal change control system (SOP/QA/015).
Changes are classified as:
- Critical: Requires regulatory approval before implementation
- Major: Requires QA approval and may require stability data
- Minor: Requires QA approval

2.6 DEVIATION AND CAPA

Deviations are investigated using root cause analysis tools (5-Why, Fishbone).
CAPAs are implemented and effectiveness verified.

Deviation Statistics (FY 2024-25):
- Total deviations: 45
- Critical: 0
- Major: 8
- Minor: 37
- Average closure time: 18 days

2.7 MANAGEMENT REVIEW

Management reviews are conducted quarterly covering:
- Quality metrics and trends
- Audit findings
- CAPA status
- Customer complaints
- Regulatory updates
- Resource requirements

================================================================================

3. PERSONNEL
===========

3.1 ORGANIZATIONAL CHART

                        Managing Director
                     Dr. Ramesh Kulkarni
                              |
            +-----------------+-----------------+
            |                 |                 |
    Technical Director   CFO              Head - Operations
    Dr. Rajendra Patil   Mr. Rajesh Sharma   Mrs. Sunita Kulkarni
            |
    +-------+-------+-------+
    |       |       |       |
  Head QA  Head QC  Production  Regulatory
  Mrs. Deepika  Dr. Anita  Manager    Head
  Jain      Shah    Mr. Suresh   Ms. Priya
                    Sharma       Desai

3.2 KEY PERSONNEL

Position                    Name                 Qualification      Experience
--------------------------------------------------------------------------------
Technical Director          Dr. Rajendra Patil   M.Pharm, Ph.D.    22 years
Head of Quality Assurance   Mrs. Deepika Jain    M.Pharm (QA)      18 years
Head of Quality Control     Dr. Anita Shah       M.Sc, Ph.D.       16 years
Production Manager          Mr. Suresh Sharma    B.Pharm           15 years
Head of Regulatory Affairs  Ms. Priya Desai      M.Pharm           12 years
Warehouse Manager           Mr. Amit Patel       B.Pharm           10 years
Engineering Manager         Mr. Vikram Singh     B.E. Mechanical   14 years
Microbiologist              Dr. Neha Verma       M.Sc Microbiology 8 years

All key personnel are employed full-time and are present during operations.

3.3 TOTAL PERSONNEL

Department              Permanent    Contract    Total
------------------------------------------------------
Production              85           40          125
Quality Control         12           4           16
Quality Assurance       8            2           10
Warehouse               15           8           23
Engineering             12           6           18
Regulatory              4            0           4
Administration          18           4           22
------------------------------------------------------
Total                   154          64          218

3.4 TRAINING

All personnel receive:
- Induction training (GMP basics, hygiene, safety)
- Job-specific training
- Annual GMP refresher training
- SOP training before implementation

Training records are maintained for all personnel.
Training effectiveness is assessed through written tests and practical evaluation.

Training Hours FY 2024-25:
- Total training hours: 4,850
- Average per employee: 22 hours

3.5 PERSONNEL HYGIENE

- Annual medical examination for all production and QC personnel
- Pre-employment medical fitness certificate
- Personnel with illness not permitted in production/QC areas
- Hand washing and sanitization procedures
- Gowning procedures for different areas
- No eating, drinking, smoking in production areas

3.6 CONSULTANTS

External consultants are used for:
- GMP audits (M/s. GMP Compliance Services, Mumbai)
- Validation services (M/s. PharmaValid Consultants, Pune)
- Regulatory submissions (M/s. RegAffairs India, Mumbai)

Consultant CVs and confidentiality agreements are on file.

================================================================================

4. PREMISES AND EQUIPMENT
========================

4.1 SITE LAYOUT

Total Plot Area:        12,000 sq. meters
Built-up Area:          7,897 sq. meters (85,000 sq. ft.)
Green Belt:             1,200 sq. meters

The site is located in MIDC Industrial Area, away from residential zones.
No environmental pollutants in vicinity.

4.2 BUILDING DESCRIPTION

Block               Area (sq.ft.)   Products/Function
--------------------------------------------------------------------------------
Block A             25,000          Non-beta-lactam tablets and capsules
Block B             8,000           Penicillins (dedicated, self-contained)
Block C             7,000           Cephalosporins (dedicated, self-contained)
Quality Control Lab 8,000           Testing laboratories
Warehouse           15,000          RM, PM, FG storage
Utilities           8,000           HVAC, water, power
Administration      10,000          Offices, canteen, change rooms
R&D                 4,000           Formulation development

4.3 MANUFACTURING AREAS

Block A - Non-Beta-Lactam:

Area                    Classification    Pressure      Temperature    Humidity
--------------------------------------------------------------------------------
Dispensing              Grade D           +15 Pa        22±3°C         45±10%
Granulation             Grade D           +15 Pa        22±3°C         45±10%
Drying                  Grade D           +15 Pa        22±3°C         45±10%
Compression             Grade D           +15 Pa        22±3°C         45±10%
Coating                 Grade D           +15 Pa        22±3°C         45±10%
Capsule Filling         Grade D           +15 Pa        22±3°C         45±10%
Primary Packing         Grade D           +15 Pa        22±3°C         45±10%
Secondary Packing       Controlled        Ambient       25±5°C         60±10%

Block B - Penicillins (Self-Contained):

- Separate entry/exit for personnel and materials
- Dedicated air handling unit with 100% fresh air
- Negative pressure relative to corridor
- No cross-traffic with other blocks
- Personnel must shower before exiting

Block C - Cephalosporins (Self-Contained):

- Similar containment as Block B
- Physically separated from Block B
- Dedicated utilities

4.4 AIR HANDLING SYSTEM

System      Areas Served         Filtration          Air Changes    Fresh Air
--------------------------------------------------------------------------------
AHU-1       Block A Granulation  Pre+Fine+HEPA       20 ACPH        20%
AHU-2       Block A Compression  Pre+Fine+HEPA       20 ACPH        20%
AHU-3       Block A Coating      Pre+Fine+HEPA       25 ACPH        30%
AHU-4       Block A Capsules     Pre+Fine+HEPA       20 ACPH        20%
AHU-5       Block A Packing      Pre+Fine            15 ACPH        20%
AHU-6       Block B (Penicillin) Pre+Fine+HEPA       20 ACPH        100%
AHU-7       Block C (Cephalosporin) Pre+Fine+HEPA   20 ACPH        100%
AHU-8       QC Laboratory        Pre+Fine+HEPA       15 ACPH        30%
AHU-9       Warehouse            Pre+Fine            10 ACPH        20%

All AHUs equipped with:
- Pre-filters (EU4)
- Fine filters (EU8)
- HEPA filters (H14, 99.995% efficiency) for Grade D areas
- Temperature and humidity control

4.5 WATER SYSTEMS

System              Generation      Storage     Distribution    Use
--------------------------------------------------------------------------------
Potable Water       MIDC supply     50 KL       SS piping       General use
Purified Water      RO + EDI        10 KL       SS 316L loop    Production
                    2000 LPH                    80°C hot water

Purified Water Specifications:
- Conductivity: NMT 1.3 µS/cm
- TOC: NMT 500 ppb
- Microbial count: NMT 100 CFU/ml

Distribution loop maintained at 80°C for microbial control.
Periodic sanitization with ozone.

4.6 MAJOR EQUIPMENT LIST

Equipment               Make/Model          Capacity        Qualification
--------------------------------------------------------------------------------
Rapid Mixer Granulator  Anchor RMG-300      300 L           IQ/OQ/PQ done
Fluid Bed Dryer         Retsch FBD-200      200 kg          IQ/OQ/PQ done
Multi-Mill              Cadmach MM-200      200 kg/hr       IQ/OQ/PQ done
Tablet Press 1          Cadmach CMD4-45     450,000/hr      IQ/OQ/PQ done
Tablet Press 2          Cadmach CMD4-45     450,000/hr      IQ/OQ/PQ done
Tablet Press 3          Fette P3000         300,000/hr      IQ/OQ/PQ done
Coating Pan             Gansons GAC-80      80 kg           IQ/OQ/PQ done
Capsule Filler          Zanasi AZ-40        40,000/hr       IQ/OQ/PQ done
Blister Pack Machine    Uhlmann UPS-300     300 blisters/min IQ/OQ/PQ done
Strip Pack Machine      Elmach SP-120       120 strips/min  IQ/OQ/PQ done
Carton Packer           Marchesini MA-150   150/min         IQ/OQ/PQ done

All equipment is:
- Made of SS 316/316L for product contact parts
- Qualified (IQ/OQ/PQ completed)
- Under preventive maintenance program
- Calibrated at defined intervals

4.7 MAINTENANCE AND CALIBRATION

Maintenance:
- Preventive maintenance schedule for all equipment
- Maintenance SOPs for each equipment
- Breakdown maintenance recorded and investigated
- Annual Maintenance Contracts with OEMs for critical equipment

Calibration:
- Master calibration schedule maintained
- Critical instruments calibrated by NABL-accredited agencies
- Calibration labels on all instruments
- Out-of-calibration instruments quarantined

4.8 CLEANING AND SANITATION

- Validated cleaning procedures for all equipment
- Cleaning validation using swab and rinse sampling
- Residue limits: <10 ppm of previous product, <10 ppm detergent
- Visual inspection plus analytical verification
- "Clean" and "To Be Cleaned" labels
- Maximum hold time after cleaning: 7 days

4.9 UTILITIES SUMMARY

Utility             Source              Capacity        Backup
--------------------------------------------------------------------------------
Electricity         MSEB + DG           2000 KVA        500 KVA DG (2 nos.)
Steam               Electric boiler     500 kg/hr       N/A
Compressed Air      Oil-free compressor 500 CFM         Standby compressor
Nitrogen            PSA generator       50 Nm³/hr       Cylinder backup
Vacuum              Central vacuum      500 CFM         N/A

================================================================================

5. DOCUMENTATION
===============

5.1 DOCUMENTATION SYSTEM

All documentation is controlled through Document Control SOP (SOP/QA/001).

Document Hierarchy:
- Level 1: Quality Manual
- Level 2: Standard Operating Procedures
- Level 3: Batch records, specifications, test methods
- Level 4: Forms, formats, logbooks

5.2 DOCUMENT STATISTICS

Document Type                   Active Documents
------------------------------------------------
Quality Manual                  1
SOPs                            287
Specifications (RM/PM/FG)       185
Test Methods                    124
Master Batch Records            47
Master Packing Records          47
Validation Protocols            156

5.3 DOCUMENT CONTROL

- All documents assigned unique numbers
- Version control maintained
- Effective date on all documents
- Controlled copies distributed
- Obsolete documents archived
- Periodic review (every 2 years)
- Electronic backup of all documents

5.4 ELECTRONIC SYSTEMS

System              Vendor          Validated    21 CFR Part 11
--------------------------------------------------------------------------------
ERP (SAP)           SAP             Yes          Compliant
LIMS                LabWare         Yes          Compliant
Document Control    MasterControl   Yes          Compliant
Training Management ComplianceWire  Yes          Compliant

================================================================================

6. PRODUCTION
============

6.1 PRODUCTION OPERATIONS

Products Manufactured:
- Tablets: 35 products
- Capsules: 12 products
- Total: 47 products

Annual Production Capacity:
- Tablets/Capsules: 2.4 billion units
- Utilization FY 2024-25: 82%

6.2 PROCESS FLOW

General Process Flow for Tablets:

Raw Material Receipt → Sampling → Testing → Approval → Storage
                                                          ↓
                                                     Dispensing
                                                          ↓
                                                     Sifting
                                                          ↓
                                                     Dry Mixing
                                                          ↓
                                                     Granulation
                                                          ↓
                                                     Drying
                                                          ↓
                                                     Sizing
                                                          ↓
                                                     Lubrication
                                                          ↓
                                                     Compression
                                                          ↓
                                                     Coating (if applicable)
                                                          ↓
                                                     Primary Packing
                                                          ↓
                                                     Secondary Packing
                                                          ↓
                                                     Quarantine
                                                          ↓
                                                     QC Testing
                                                          ↓
                                                     QA Release
                                                          ↓
                                                     Finished Goods Store

6.3 PROCESS VALIDATION

All products are process validated:
- Prospective validation for new products
- Concurrent validation for existing products
- Revalidation after significant changes

Validation approach:
- 3 consecutive batches at commercial scale
- In-process controls and finished product testing
- Statistical analysis of results
- Validation report with conclusions

6.4 CROSS-CONTAMINATION PREVENTION

Measures implemented:
- Dedicated facilities for beta-lactams
- Pressure cascades between areas
- Validated cleaning procedures
- Campaign manufacturing for similar products
- Airlock systems
- Dedicated equipment where necessary

6.5 MATERIAL MANAGEMENT

Raw Materials:
- Received in dedicated receiving bay
- Quarantined until approved
- Stored in approved storage conditions
- FIFO/FEFO system
- Dispensing in controlled environment
- Reconciliation at each stage

Packaging Materials:
- Printed materials under lock and key
- Version control and reconciliation
- Destruction of obsolete materials

================================================================================

7. QUALITY CONTROL
=================

7.1 QC LABORATORY

Location:           Separate building adjacent to production
Area:               8,000 sq. ft.
Accreditation:      NABL (ISO/IEC 17025)
Certificate No.:    TC-5678

7.2 LABORATORY AREAS

Area                    Purpose                     Classification
--------------------------------------------------------------------------------
Chemical Testing        Wet chemistry, HPLC, UV     Controlled
Instrumental Analysis   HPLC, GC, IR, Dissolution   Controlled
Microbiology           Sterility, Microbial limits  Grade D/C
Stability              Stability storage & testing  Temperature controlled
Reference Standards    Storage of RS and WS         Temperature controlled
Retained Samples       Storage of retention samples Controlled

7.3 MAJOR INSTRUMENTS

Instrument              Quantity    Make              Last Calibration
--------------------------------------------------------------------------------
HPLC                    3           Waters, Shimadzu  October 2025
UV-Vis Spectrophotometer 2          Shimadzu          October 2025
Dissolution Apparatus   12 vessels  Electrolab        October 2025
Disintegration Tester   2           Electrolab        October 2025
IR Spectrophotometer    1           Bruker            September 2025
Karl Fischer Titrator   2           Metrohm           October 2025
pH Meter                3           Mettler Toledo    September 2025
Analytical Balance      6           Mettler Toledo    September 2025
Stability Chambers      4           Thermolab         October 2025

7.4 TESTING ACTIVITIES

Raw Materials:
- Identity, assay, related substances
- Physical tests
- Microbial limits

In-Process Controls:
- Blend uniformity
- Moisture content
- Hardness, weight variation
- Disintegration, friability

Finished Products:
- Full testing as per specification
- Dissolution profiles
- Stability testing

7.5 STABILITY PROGRAM

- ICH Q1A/Q1B guidelines followed
- Long-term: 30°C/65% RH (Zone III)
- Accelerated: 40°C/75% RH
- At least 1 batch per product per year
- Photostability studies for new products

7.6 REFERENCE STANDARDS

- Pharmacopeial reference standards (USP, EP, IP)
- Working standards qualified against primary standards
- Storage under controlled conditions
- Certificate of Analysis maintained

7.7 OUT-OF-SPECIFICATION (OOS) INVESTIGATIONS

- All OOS results investigated per SOP/QC/045
- Phase 1: Laboratory investigation (analyst error, instrument malfunction)
- Phase 2: Manufacturing investigation (if lab confirmed)
- Decision tree for retesting
- CAPA for confirmed OOS

OOS Statistics FY 2024-25:
- Total OOS: 12
- Laboratory error: 5
- Manufacturing related: 4
- Confirmed OOS (batch rejected): 3

================================================================================

8. DISTRIBUTION, COMPLAINTS, AND RECALLS
=======================================

8.1 DISTRIBUTION

Products are distributed through:
- Company warehouse to distributors
- Direct to large customers
- Export via shipping/air freight

Cold chain maintained for temperature-sensitive products.
Distribution records enable complete traceability.

8.2 COMPLAINTS

Complaint handling per SOP/QA/056:
- All complaints logged in database
- Investigated within 30 days
- Trend analysis performed
- CAPA implemented for recurring issues

Complaint Statistics FY 2024-25:
- Total complaints: 42
- Quality related: 18
- Packaging related: 12
- Delivery related: 8
- Other: 4

8.3 PRODUCT RECALLS

Recall procedure per SOP/QA/078:
- Recall team designated
- Classification: Class I, II, III
- Communication to customers and regulators
- Recovery and destruction

Recall History:
- One recall in 2019 (Paracetamol batch - dissolution failure)
- 94% recovery achieved
- Mock recalls conducted annually

================================================================================

9. SELF-INSPECTION
=================

9.1 INTERNAL AUDIT PROGRAM

Frequency: Quarterly covering all areas
Audit team: Trained internal auditors
Schedule: Annual audit schedule prepared

Audit Areas:
- Q1: Manufacturing and documentation
- Q2: QC laboratory
- Q3: Warehouse and materials
- Q4: Equipment and utilities

9.2 AUDIT FINDINGS

FY 2024-25 Internal Audit Summary:
- Total observations: 28
- Critical: 0
- Major: 4
- Minor: 24
- Average closure time: 21 days

9.3 EXTERNAL AUDITS

- Annual GMP audit by external consultant
- Customer audits (3-4 per year)
- Regulatory inspections

================================================================================

10. APPENDICES
=============

Appendix 1: Site Layout Drawing
Appendix 2: Organizational Chart
Appendix 3: Product List
Appendix 4: Equipment List
Appendix 5: GMP Certificates
Appendix 6: Personnel Training Matrix

================================================================================

REVISION HISTORY

Version   Date           Changes                        Approved By
--------------------------------------------------------------------------------
1.0       Jan 2013       Initial release                Dr. R. Kulkarni
2.0       Jan 2016       Added Block B&C, updated       Dr. R. Kulkarni
                         equipment list
3.0       Jan 2019       Updated for WHO-GMP            Dr. R. Kulkarni
                         certification
4.0       Jan 2022       Updated personnel, equipment   Dr. R. Kulkarni
5.0       Jan 2025       Annual review and update       Dr. R. Kulkarni

================================================================================
                    END OF SITE MASTER FILE
================================================================================
